# A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

> **NCT07124078** · PHASE2 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** INCA034176
- **DRUG:** Best available Treatment (BAT)

## Key facts

- **NCT ID:** NCT07124078
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07124078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07124078, "A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT07124078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*